Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF
Status:
Withdrawn
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Anti-cytokine antibodies, such as Infliximab (an anti TNF alfa chimeric antibody) and
Adalimumab (an anti TNF alfa humanize antibody), have been developed and used in clinical
practice for the treatment of patients with Crohn disease (CD). Unfortunately, their efficacy
is limited. Based on these concepts, a new drug has been developed for IBD treatment.
Vedolizumab (VDZ) is able to recognize the α4β7 heterodimer, and selectively blocks gut
lymphocyte trafficking.
The hypothesis of this study is that VDZ therapy may be to halt CD disease progression during
time and modifying its natural history, using Lemann Index.